Novartis’ Asthma Med, Inhaler and Sensor Cleared in Europe

Novartis has received European Commission approval for its Enerzair Breezhaler, which provides maintenance treatment of asthma in adults. The device also received CE mark certification for an optional attachable sensor that records each administered dose.

The triple-combination medication — indacaterol acetate, glycopyrronium bromide and mometasone furoate — is administered using the dose-confirming Breezhaler inhaler device once daily and comes in a transparent capsule that allows patients to see they have successfully taken the medication.

The optional sensor attaches to the inhaler and can be synced up with a smartphone app to provide inhalation confirmation, reminders and data that can be shared with physicians. The sensor includes a microphone, an antenna, a battery and Bluetooth device functionality.